<p>Drugmakers will be offered fast-tracked approvals for innovative medicines in the UK, in an effort to attract investments from life sciences companies after Brexit, the Financial Times reported on Sunday.</p>.<p>Companies that promise to treat unmet medical needs will be offered help through the development process, including manufacturing, the newspaper said, citing three people familiar with the matter.</p>.<p>Companies are set to be offered the same rolling review of data that expedited approval of the Pfizer and BioNTech Covid-19 vaccine under the so-called Innovative Licensing and Access Pathway, the FT reported.</p>
<p>Drugmakers will be offered fast-tracked approvals for innovative medicines in the UK, in an effort to attract investments from life sciences companies after Brexit, the Financial Times reported on Sunday.</p>.<p>Companies that promise to treat unmet medical needs will be offered help through the development process, including manufacturing, the newspaper said, citing three people familiar with the matter.</p>.<p>Companies are set to be offered the same rolling review of data that expedited approval of the Pfizer and BioNTech Covid-19 vaccine under the so-called Innovative Licensing and Access Pathway, the FT reported.</p>